A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

Exclusion Criteria

• •1. Subjects who cannot complete INR101 imaging according to the requirements
• •2. Subjects who cannot complete pharmacokinetics sample collection according to the requirements
• •3. Serum virology examination (Heptitis B surface antigen,Anti-Treponema pallidum antibody,HIV antibodies,Antibody to Hepatitis C Virus) is abnormal, which is judged by the researchers to have clinical significance
• •4. History of mental illness
• •5. History of past malignant tumors
• •6. History of past heart-related diseases
• •7. History of significant brain diseases in the past
• •8. Suffering from severe and/or poorly controlled and/or unstable diseases that the researcher judges may affect the study
• •9. History of bleeding or coagulation disorders
• •10. History of alcohol abuse or drug abuse/dependency
• •11. Known allergy to the active ingredients of INR101 or its components
• •12. Participated in other clinical trials before screening or during screening, or plans to participate in other clinical trials during this study
• •13. The researcher judges that there are any medical diseases or other conditions that may affect safety, compliance or may affect the results of the study
• •1. Subjects who are unable to complete the INR101 imaging as required
• •2. History of any other malignant tumors in the past
• •3. Subjects in other interventional clinical trials or subjects in clinical trials of radioactive therapeutic drugs before signing the informed consent form
• •4. Receiving any anti-tumor treatment before drug administration
• •5. Known allergy to the active ingredients of INR101 or its components Abnormal serum virology examination
• •6. Researchers judge that there are any medical diseases or other conditions that may affect safety, compliance or may affect the study results.